A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: A systematic review

Keyphrases

• Tyrosine Kinase Inhibitor 100%
• Pharmacogenomics 100%
• Metastatic Renal Cell Carcinoma (mRCC) 100%
• Treatment Outcome 40%
• Potential Biomarkers 40%
• Predictive Biomarker 20%
• Renal Cell Carcinoma 20%
• Targeted Therapy 20%
• Pharmacokinetics 20%
• Pharmacodynamics 20%
• Genetic Variants 20%
• Cancer Patients 20%
• Clinical Implementation 20%
• Pharmacogenetics 20%
• Biomarker Testing 20%
• Tyrosine Kinase Inhibitor Treatment 20%
• Individual Response 20%
• Medical Database 20%
• Therapy Choice 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Pharmacogenomics 100%
• Biological Marker 80%
• Pharmacodynamics 20%
• Pharmacogenetics 20%
• Renal Cell Carcinoma 20%
• Pharmacokinetics 20%

Biochemistry, Genetics and Molecular Biology

• Tyrosine Kinase Inhibitor 100%
• Cancer Cell 100%
• Pharmacogenomics 100%
• Genetic Divergence 20%
• Pharmacokinetics 20%
• Pharmacogenetics 20%
• Pharmacodynamics 20%